# APBA Kısa Özet

The Entebbe Mother and Baby Study (EMaBS) is a longitudinal cohort established in 2001 in Uganda that recruited 2,507 pregnant women and 2,345 live-born children to investigate the effects of helminth treatment during pregnancy and early childhood on vaccine responses, immune development, and long-term health outcomes, including allergy, blood pressure, and vaccine genetics.

# Çalışma neyi araştırdı?

The Entebbe Mother and Baby Study (EMaBS) was established in 2001 to test the hypothesis that treating helminth infections during pregnancy and early childhood could improve children's responses to Bacillus Calmette-Guérin (BCG) and other vaccines given in infancy and influence immune responses to other infectious pathogens. The cohort was created to address a longstanding question in global health: whether helminth-induced immune modulation could enhance vaccine efficacy or alter the trajectory of immune-related conditions such as allergy and hypertension. Over two decades of follow-up have allowed researchers to examine both early infant outcomes and longer-term health trajectories.

# Yöntem

EMaBS recruited 2,507 pregnant women attending antenatal services at Entebbe General Hospital, Uganda. Women were enrolled during pregnancy and randomised to receive albendazole or placebo. After delivery, children were randomised to receive albendazole or placebo during early childhood. The study design combined antenatal and postnatal anthelmintic treatment arms, creating four exposure groups: no treatment, maternal only, child only, and both. Primary outcomes included infant vaccine responses (particularly to BCG and tetanus), incidence of infectious diseases, growth parameters, and allergic outcomes. Blood samples, stool examinations, and clinical data were collected at defined intervals. Epigenetic profiling, genetic analyses, and blood pressure monitoring were incorporated into later follow-up phases. The extended follow-up beyond the initial trial period is observational, which introduces specific methodological considerations regarding maintenance of treatment allocation and loss to follow-up.

# Temel bulgular

  • Recruitment and scale: 2,507 pregnant women were recruited at Entebbe General Hospital; 2,345 live-born children were enrolled into the birth cohort.
  • Safety: Maternal albendazole treatment was shown to be safe and reduced anaemia in mothers with heavy hookworm infections.
  • Infant vaccine response: Maternal anthelmintic treatment had small effects on infant response to tetanus immunisation, but no beneficial or detrimental effect on the occurrence of infectious diseases in childhood.
  • Allergic outcomes: Treatment of helminths during pregnancy resulted in increased rates of eczema in early childhood, although this association was not sustained to nine years of age.
  • Blood pressure: Emerging data have explored associations between early helminth exposure and later blood pressure trajectories, though findings remain imprecise.
  • Genetic sub-studies: Investigations into vaccine genetics and host immune gene expression have been integrated into the cohort’s secondary analyses.

# Bulgular ne anlama geliyor?

The EMaBS findings contribute nuanced evidence to the debate on helminth modulation of vaccine efficacy and immune development. The observation that maternal treatment reduced maternal anaemia supports the clinical benefit of deworming in high-prevalence settings, even if infant vaccine responses were largely unaffected. The transient increase in early childhood eczema following prenatal treatment suggests a possible short-term immune rebalancing effect that does not persist, aligning with the "hygiene hypothesis" nuance that early immune exposures may have window-specific effects. The lack of impact on childhood infectious disease occurrence suggests that helminth treatment, at least in this setting, does not simply shift susceptibility to common infections. Overall, the cohort underscores the complexity of manipulating helminth infections for immune benefit and highlights the importance of context-specific evidence.

# Klinik önem

The EMaBS cohort provides critical real-world evidence on the safety and immunological consequences of anthelmintic treatment during the perinatal period. The finding that albendazole reduced anaemia in mothers with heavy hookworm infections has direct implications for maternal health policy in endemic regions. However, the lack of consistent benefit—and the transient allergic signal—on infant vaccine responses and infectious disease risk suggests that routine deworming solely to enhance vaccine efficacy cannot be recommended based on current evidence. Clinicians and policymakers should weigh maternal anaemia prevention against the possibility of short-term immunomodulatory effects when implementing helminth control programmes in pregnancy. Continued follow-up of the EMaBS cohort will be essential for elucidating long-term non-communicable disease risks associated with early-life helminth exposure.

# Sınırlılıklar

The EMaBS cohort profile and associated findings are subject to several important limitations. The extended follow-up beyond the original randomised controlled trial period is observational, meaning that treatment allocation cannot be maintained with certainty and potential contamination between groups may have occurred. Precision of effect estimates may be limited by the cohort size, particularly for rare outcomes. Generalizability beyond the Uganda setting is unclear, as genetic, environmental, and helminth species factors differ substantially across populations. Loss to follow-up over more than 20 years of observation may affect the completeness of outcome data. Additionally, epigenetic and long-term non-communicable disease (NCD) outcomes are still under investigation, and the observational nature of the extension phases limits causal inference regarding late-life health effects.